LATISSE

AbsorptionAfter one drop of bimatoprost ophthalmic solution 0.03% was administered once daily into both eyes (cornea and/or conjunctival sac) of 15 healthy subjects for two weeks, blood concentrations peaked within 10 minutes after dosing and were below the lower limit of detection (0.025 ng/mL) in most subjects within 1.5 hours after dosing. Mean C max and AUC 0-24hr values were similar on days 7 and 14 at approximately 0.08 ng/mL and 0.09 ng●hr/mL, respectively, indicating that steady state w...

LATISSE ® solution was evaluated for its effect on overall eyelash prominence in a multicenter, double-masked, randomized, vehicle-controlled, parallel study including 278 adult patients for four months of treatment. The primary efficacy endpoint in this study was an increase in overall eyelash prominence as measured by at least a 1-grade increase on the 4-point Global Eyelash Assessment (GEA) scale, from baseline to the end of the treatment period (week 16). LATISSE ® was more effective than vehicle as measured by the GEA score, with statistically significant differences seen at 8-week, 12-we...

The following adverse reactions are described elsewhere in the labeling: Effects on Intraocular Pressure [see Warnings and Precautions (5.1) ] Iris Pigmentation [see Warnings and Precautions (5.2) ] Lid Pigmentation [see Warnings and Precautions (5.3) ] Hair Growth Outside the Treatment Area [see Warnings and Precautions (5.4) ] Intraocular Inflammation [see Warnings and Precautions (5.5) ] Macular Edema [see Warnings and Precautions (5.6) ] Hypersensitivity [see Contraindications (4) ] M...

LATISSE ® is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see Adverse Reactions (6.2) ]. Hypersensitivity. ( 4 )

Concurrent administration of LATISSE ® and intraocular pressure (IOP)-lowering prostaglandin analogs in ocular hypertensive patients may decrease the IOP-lowering effect. Patients using these products concomitantly should be closely monitored for changes to their IOP. ( 5.1 ) Pigmentation of the eyelids and iris may occur. Iris pigmentation is likely to be permanent. ( 5.2 , 5.3 ) 5.1 Effects on Intraocular Pressure Bimatoprost ophthalmic solution ( LUMIGAN ® ) lowers intraocular pressure (IOP) ...